350 related articles for article (PubMed ID: 37234016)
21. Paying for Drugs After the Medicare Part D Beneficiary Reaches the Catastrophic Limit: Lessons on Cost Sharing from Other US Policy Partnerships Between Government and Commercial Industry.
Padula WV; Ballreich J; Anderson GF
Appl Health Econ Health Policy; 2018 Dec; 16(6):753-763. PubMed ID: 30058011
[TBL] [Abstract][Full Text] [Related]
22. Out-of-Pocket Drug Costs for Medicare Beneficiaries With Cardiovascular Risk Factors Under the Inflation Reduction Act.
Narasimmaraj PR; Oseran A; Tale A; Xu J; Essien UR; Kazi DS; Yeh RW; Wadhera RK
J Am Coll Cardiol; 2023 Apr; 81(15):1491-1501. PubMed ID: 37045519
[TBL] [Abstract][Full Text] [Related]
23. Prescription Drug Coverage for Treatment of Low Back Pain Among US Medicaid, Medicare Advantage, and Commercial Insurers.
Lin DH; Jones CM; Compton WM; Heyward J; Losby JL; Murimi IB; Baldwin GT; Ballreich JM; Thomas DA; Bicket M; Porter L; Tierce JC; Alexander GC
JAMA Netw Open; 2018 Jun; 1(2):e180235. PubMed ID: 30646077
[TBL] [Abstract][Full Text] [Related]
24. Prescription coverage, use and spending before and after Part D implementation: a national longitudinal panel study.
Safran DG; Strollo MK; Guterman S; Li A; Rogers WH; Neuman P
J Gen Intern Med; 2010 Jan; 25(1):10-7. PubMed ID: 19882193
[TBL] [Abstract][Full Text] [Related]
25. Sociodemographic and spending characteristics of Medicare beneficiaries taking prescription drugs subject to price negotiations.
Odouard IC; Anderson GF; Alexander GC; Ballreich J
J Manag Care Spec Pharm; 2024 Mar; 30(3):269-278. PubMed ID: 38140901
[TBL] [Abstract][Full Text] [Related]
26. Health Care Utilization and Spending in Medicare Advantage vs Traditional Medicare: A Difference-in-Differences Analysis.
Schwartz AL; Zlaoui K; Foreman RP; Brennan TA; Newhouse JP
JAMA Health Forum; 2021 Dec; 2(12):e214001. PubMed ID: 35977297
[TBL] [Abstract][Full Text] [Related]
27. Cost minimization of medicare part D prescription drug plan expenditures.
Patel RA; Lipton HL; Cutler TW; Smith AR; Tsunoda SM; Stebbins MR
Am J Manag Care; 2009 Aug; 15(8):545-53. PubMed ID: 19670958
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of Spending Differences Between Beneficiaries in Medicare Advantage and the Medicare Shared Savings Program.
Parikh RB; Emanuel EJ; Brensinger CM; Boyle CW; Price-Haywood EG; Burton JH; Heltz SB; Navathe AS
JAMA Netw Open; 2022 Aug; 5(8):e2228529. PubMed ID: 35997977
[TBL] [Abstract][Full Text] [Related]
29. Effect of Generic Competition on Atorvastatin Prescribing and Patients' Out-of-Pocket Spending.
Luo J; Seeger JD; Donneyong M; Gagne JJ; Avorn J; Kesselheim AS
JAMA Intern Med; 2016 Sep; 176(9):1317-23. PubMed ID: 27367749
[TBL] [Abstract][Full Text] [Related]
30. Trends in Prices, Market Share, and Spending on Self-administered Disease-Modifying Therapies for Multiple Sclerosis in Medicare Part D.
San-Juan-Rodriguez A; Good CB; Heyman RA; Parekh N; Shrank WH; Hernandez I
JAMA Neurol; 2019 Nov; 76(11):1386-1390. PubMed ID: 31449293
[TBL] [Abstract][Full Text] [Related]
31. The impact of Medicare prescription drug coverage on the use of antidementia drugs.
Fowler NR; Chen YF; Thurton CA; Men A; Rodriguez EG; Donohue JM
BMC Geriatr; 2013 Apr; 13():37. PubMed ID: 23621892
[TBL] [Abstract][Full Text] [Related]
32. Employer drug benefit plans and spending on prescription drugs.
Joyce GF; Escarce JJ; Solomon MD; Goldman DP
JAMA; 2002 Oct; 288(14):1733-9. PubMed ID: 12365957
[TBL] [Abstract][Full Text] [Related]
33. Out-of-Pocket and Health Care Spending Changes for Patients Using Orally Administered Anticancer Therapy After Adoption of State Parity Laws.
Dusetzina SB; Huskamp HA; Winn AN; Basch E; Keating NL
JAMA Oncol; 2018 Jun; 4(6):e173598. PubMed ID: 29121177
[TBL] [Abstract][Full Text] [Related]
34. Medicare part D after 2 years.
Joyce GF; Goldman DP; Vogt WB; Sun E; Jena AB
Am J Manag Care; 2009 Aug; 15(8):536-44. PubMed ID: 19670957
[TBL] [Abstract][Full Text] [Related]
35. The effects of coding intensity in Medicare Advantage on plan benefits and finances.
Jacobs PD; Kronick R
Health Serv Res; 2021 Apr; 56(2):178-187. PubMed ID: 33165932
[TBL] [Abstract][Full Text] [Related]
36. Trends in Medicare Part D coverage of generics with equivalent brand-name drugs.
Dusetzina SB; Cubanski J; Roberts AW; Hoadley J; True S; Nshuti L; Neuman T
Am J Manag Care; 2021 Jul; 27(7):283-288. PubMed ID: 34314117
[TBL] [Abstract][Full Text] [Related]
37. Five-year impact of Medicare Part D coverage gap reform on drug expenditures and utilization.
Park J; Look KA
Health Serv Res; 2022 Feb; 57(1):56-65. PubMed ID: 33870486
[TBL] [Abstract][Full Text] [Related]
38. Association Between Care Management and Outcomes Among Patients With Complex Needs in Medicare Accountable Care Organizations.
Ouayogodé MH; Mainor AJ; Meara E; Bynum JPW; Colla CH
JAMA Netw Open; 2019 Jul; 2(7):e196939. PubMed ID: 31298714
[TBL] [Abstract][Full Text] [Related]
39. Implementation of Medicare Part D and nondrug medical spending for elderly adults with limited prior drug coverage.
McWilliams JM; Zaslavsky AM; Huskamp HA
JAMA; 2011 Jul; 306(4):402-9. PubMed ID: 21791689
[TBL] [Abstract][Full Text] [Related]
40. Out-of-Pocket Spending for Non-Birth-Related Hospitalizations of Privately Insured US Children, 2017 to 2019.
Carlton EF; Becker NV; Moniz MH; Scott JW; Prescott HC; Chua KP
JAMA Pediatr; 2023 May; 177(5):516-525. PubMed ID: 36972040
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
